Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Chitogenx Inc C.CHGX

Alternate Symbol(s):  CHNXF

ChitogenX Inc. is a Canada-based emerging orthopedic and sports medicine biologics company. The Company is engaged in the development of therapeutic soft tissue repair technologies to improve the success rate of orthopedic and sports medicine surgeries. The Company’s proprietary biopolymer has been specifically designed to increase the healing rates of occupational and sports related injuries to tendons, ligaments, meniscus and cartilage. The biopolymer, autologous platelet-rich plasma (PRP) combination implant, can be directly placed into the site of injuries by surgeons during routine operative procedures without significantly extending the duration of surgeries and without further interventions. The Company assess its potential for therapeutic uses outside of the soft tissue repair market. The Company, through Ecole Polytechnique and two industrial partners, delineates the PRP components, the distinct impact of each component and their collective action towards tissue repair.


CSE:CHGX - Post by User

Chitogenx Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1836)
•••
Post by Betteryear2on May 04, 2022 3:32pm
123 Views
Post# 34656177

RECEIVES KEY U.S. COMPOSITION AND METHOD PATENT CSE: ORTH

RECEIVES KEY U.S. COMPOSITION AND METHOD PATENT CSE: ORTH
  • New patent issued by U.S. Patent and Trademark Office to protect core IP until 2035
     
  • Positions Company as leading player in the dynamic regenerative medicine market
     
  • Enables delivery of PRP in soft tissue repair surgery in a proprietary way

MONTREAL, May 4, 2022 /PRNewswire/ - Ortho Regenerative Technologies Inc. (CSE: ORTH) (OTC: ORTIF) ("Ortho" or the "Company"), a clinical-stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, announced today that the United States Patent and Trademark Office (the "USPTO") has issued a patent related to the Company's ORTHO-R soft tissue repair platform
 

https://www.prnewswire.com/news-releases/ortho-regenerative-technologies-receives-key-us-composition-and-method-patent-for-ortho-r-soft-tissue-repair-platform-301539419.html

 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities